Potential and Challenges of Christensenella minuta as a Next-Generation Probiotic

Christensenella minuta, a Gram-negative, strictly anaerobic gut bacterium, has emerged as a promising next-generation probiotic due to its strong association with leanness and metabolic health. This review synthesizes current evidence on its multifaceted benefits, including the regulation of lipid and glucose homeostasis via bile acid modulation and short-chain fatty acid production, immunomodulation through NF-κB pathway inhibition, and the enhancement of gut-barrier integrity. Additionally, C. minuta demonstrates protective roles in liver injury, gut-brain-axis communication, and polycystic ovary syndrome via butyrate-mediated mechanisms. However, challenges such as oxygen sensitivity during production, strain-specific effects, and limited long-term safety data hinder clinical translation. Future research must prioritize optimized cultivation, rigorous clinical trials, and strain-level characterization to harness its full therapeutic potential for metabolic and inflammatory diseases.